100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
NR 566 Final Study Guide Questions And Answers $13.49   Add to cart

Exam (elaborations)

NR 566 Final Study Guide Questions And Answers

 4 views  0 purchase
  • Course
  • NR 566
  • Institution
  • NR 566

NR 566 Final Study Guide Questions And Answers NR 566 Final Study Guide Questions And Answers NR 566 Final Study Guide Questions And Answers

Preview 4 out of 84  pages

  • September 12, 2024
  • 84
  • 2024/2025
  • Exam (elaborations)
  • Questions & answers
  • NR 566
  • NR 566
avatar-seller
lectjoseph
NR 566 Final Study Guide
Week 1

Ch 50 estrogen and progestins - ANS



Menopause

1. is the associated loss of estrogen which typically begins

2. During the initial phase, the menstrual cycle becomes

3. Eventually, ovulation and menstruation - ANS 1. at approximately age 51 to 52 years, with 95% of
women entering menopause between the ages of 45 and 55 years.

2. irregular, anovulatory cycles may occur, and periods of amenorrhea may alternate with menses

3. cease entirely



Physiologic Alterations Accompanying Menopause

1. Vasomotor Symptoms; hot flashes and night sweats) develop in approximately

2. Genitourinary Syndrome of Menopause; the urethra and vagina have the highest

3. Mental Changes; Many women report

4. Bone Loss; In the absence of estrogen, bone resorption accelerates, leading

5. Altered Lipid Metabolism; studies have shown increases in

6. Female Sexual Interest-Arousal Disorder - ANS 1. 70% of postmenopausal women. Episodes are
characterized by sudden skin flushing, sweating, and a sensation of uncomfortable warmth. These
episodes can occur at night, resulting in drenching sweats

2. concentrations of ERs; when estrogen levels decline during menopause, these structures begin to
atrophy resulting in urge incontinence and urinary frequency; Urethritis and UTIs can also occur

3. cognitive changes such as difficulty in problem solving and short-term memory loss. Others
experience depression or an increase in anxiety

4. to a 12% loss of bone density leading to Osteoporosis which can cause compression fractures of
the vertebrae causing a decrease in height and produce a hump. In osteoporotic women, fractures of
the hip and wrist can result from minimal trauma

5. LDL cholesterol & decreases in HDL cholesterol. which play a role in the increase in CV disease
after menopause.

6. more common during this stage of life



Estrogen

,Therapeutic Uses:

1. Menopausal hormone therapy- When estrogen is used for this purpose,

2. Female hypogonadism-In the absence of ovarian estrogens,

3. Acne-Estrogens, in the form of

4. Cancer palliation-sometimes used for palliative therapy

5. Gender-affirmation therapy-for - ANS 1. it is usually accompanied by the use of progestins

2. pubertal transformation will not take place. (variety of causes see pg 428) This treatment
promotes breast development, maturation of the reproductive organs, and pubic and axillary hair.
This tx regimen consists of continuous low-dose therapy (for approx a year) followed by cyclic
administration of estrogen in higher doses

3. oral contraceptives, can help control acne. Tx is limited to patients at least 14-15 years old who
want contraception

4. in management of advanced prostate CA in men and in a select type of metastatic breast CA in
men& women

5. transgender women; not approved by the FDA) but prescribed off-label



Forms of Estrogen

1. Estrogen is available in conjugated and esterified forms. Esterified estrogens

2. Until mid-2016, synthetic conjugated estrogens A (Cenestin) and B (Enjuvia) were available;
however,

3. Phytoestrogens (plant-based compounds)-commonly used by women as a

4. Phytoestrogens are not as potent as estradiol, but they carry some of the same risks.

5. Selective estrogen receptor modulators (SERMs) are drugs that activate ERs in some tissues and
block them in others. These drugs were developed in an effort - ANS 1. are plant based; conjugated
estrogens are natural preparations derived from the urine of pregnant horses.

2. the manufacturer has withdrawn them from the market

3. "natural" way to manage symptoms associated with menopause

4. Women should not use phytoestrogens if they have a history of thromboembolic events or a
personal or family history of breast, uterine, or ovarian cancer.

5. to provide the benefits of estrogen (e.g., protection against osteoporosis, maintenance of the
urogenital tract, reduction of LDL cholesterol) while avoiding its drawbacks (e.g., promotion of
breast cancer, uterine cancer, and thromboembolism)



Estrogen-Adverse Effects

1. principal concerns with estrogen therapy are the potential for

,2. endometrial hyperplasia and endometrial cancer can be resolved

3. Estrogens have been associated with what common SE

4. menopause may produce or uncover

5. Nausea is the most

6. (blank) a patchy brown facial discoloration, though not dangerous, may cause significant distress -
ANS 1. endometrial hyperplasia, endometrial cancer, breast cancer, and cardiovascular
thromboembolic events

2. by prescribing a progestin

3. Fluid retention with edema, gallbladder disease, jaundice, and headache; especially migraine
headache

4. gallbladder disease. Jaundice may develop in women with preexisting liver dysfunction, especially
those who experienced cholestatic jaundice of pregnancy

5. frequent undesired response to the estrogens

6. Chloasma,



Contraindications of Estrogen

1. Estrogens should not be taken by patients with a history of

2. They should not be prescribed to women who

3. Patients with a hx of - ANS 1. DVT, pulmonary embolus, or conditions such as stroke or MI that
occurred secondary to a thromboembolic event.

2. are pregnant or who have vaginal bleeding without a known cause.

3. liver disease, estrogen-dependent tumors, or breast cancer (except when indicated for
management) also should not take estrogens.



Estrogen-Interactions

1. Estrogens are major substrates of

2. In addition, they may decrease the effectiveness of some

3. Estrogens can also interact with - ANS 1. CYP1A2 and CYP3A4; inducers/inhibitors of these
isoenzymes may raise/lower estrogen levels

2. antidiabetic drugs and thyroid preparations.

3. anticoagulants and other drugs that affect clotting.



Local vs. systemic estrogen options and why one would be chosen over the other

, 1. Oral-Owing to convenience, the oral route is used

2. Transdermal estradiol is available in four formulations:

3. Compared with oral formulations, transdermal formulations have four advantages:

4. Intravaginal options come as inserts, creams, and vaginal rings &

5. The other vaginal ring (Femring) is used for systemic effects to

6. Parenteral; is used only for emergencies d/t - ANS 1. more than any other. estradiol—is available
alone and in combination with progestin

2. Emulsion (Estrasorb), Spray, Gels & Patches

3a. The total dose of estrogen is greatly reduced

3b. There is less nausea and vomiting.

3c. Blood levels of estrogen fluctuate less.

3d. There is a lower risk for DVT, pulmonary embolism, and stroke.

4. are used only for local effects, primarily treatment of vulval and vaginal atrophy associated with
menopause.

5. control of hot flashes and night sweats as well as local effects-Tx of vulval and vaginal atrophy

6. acute, emergency control of heavy uterine bleeding



Clinical Practice Guidelines for menopause

Not all women who experience distressing symptoms of menopause should be treated with oral
estrogen or combination estrogen/progestin therapy. Key points include:

1. intravaginal preparations are most useful for treating sx associated

2. transdermal estrogen preparations have fewer adverse effects, use lower doses of estrogen, and
have

3. progesterone is contraindicated in women who have undergone a - ANS 1. with local estrogen
deficiency such as vaginal and vulvar atrophy; these preparations are assoc with a lower risk of
systemic effects

2. less fluctuation of estrogen levels than do oral preparations

3. hysterectomy but required in women with an intact uterus who undergone hormone replacement
therapy



Summary of Key Prescribing Considerations -Estrogens

1. Therapeutic Goal: Management of symptoms and structural changes associated

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller lectjoseph. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $13.49. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

76800 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$13.49
  • (0)
  Add to cart